Testosterone Undecanoate Patent Expiration

1. Aveed patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO OPERATIONS Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(2 years from now)

US8338395 ENDO OPERATIONS Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 05, 2017

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE

How can I launch a generic of AVEED before it's drug patent expiration?
More Information on Dosage

AVEED family patents

Family Patents

2. Jatenzo patent expiration

JATENZO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11179402 TOLMAR Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Apr, 2026

(1 year, 8 months from now)

US10617696 TOLMAR Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11331325 TOLMAR Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Jan, 2027

(2 years from now)

US8241664 TOLMAR Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Mar, 2029

(4 years from now)

US11179403 TOLMAR Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(5 years from now)

US10543219 TOLMAR Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(5 years from now)

US11426416 TOLMAR Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(5 years from now)

US8778916 TOLMAR Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(5 years from now)

US8492369 TOLMAR Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Dec, 2030

(6 years from now)

US11564933 TOLMAR Methods of treating testosterone deficiency
Apr, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 27, 2022

Market Authorisation Date: 27 March, 2019

Treatment: Method of treating testosterone deficiency; A method of treating testosterone deficiency in men; Testosterone replacement therapy in males for conditions associated with a deficiency or absence of end...

Dosage: CAPSULE

More Information on Dosage

JATENZO family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Kyzatrex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590146 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(6 years from now)

US10576089 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(6 years from now)

US10576090 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(6 years from now)

US11617758 MARIUS PHARMS LLC Emulsion formulations
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 27, 2025

Market Authorisation Date: 27 July, 2022

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE

More Information on Dosage

KYZATREX family patents

Family Patents

4. Tlando patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304960 VERITY Steroidal compositions
Jan, 2029

(4 years from now)

US8865695 VERITY Steroidal compositions
Jan, 2029

(4 years from now)

US8778922 VERITY Steroidal compositions
Jan, 2029

(4 years from now)

US11364249 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11433083 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US10716794 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US9949985 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11311555 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US10226473 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US9943527 VERITY High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

US11559530 VERITY Oral testosterone undecanoate therapy
Nov, 2037

(13 years from now)

US11464735 VERITY Fixed dose oral testosterone undecanoate compositions and use thereof
Apr, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2025

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE

More Information on Dosage

TLANDO family patents

Family Patents